<\/p>\n
Rcifax<\/strong> este rifaximin 400 mg or 550 mg<\/strong> — a non-absorbable rifamycin antibiotic that acts almost entirely within the gut lumen. Three validated indications: traveller’s diarrhoea (non-invasive E. coli), prevention of overt hepatic encephalopathy in cirrhosis, and IBS-D (diarrhoea-predominant irritable bowel)<\/strong>. Less than 0.4 percent of an oral dose is absorbed systemically, so off-target side effects, drug interactions, and resistance pressure on commensal bacteria are minimal. WHO-GMP certified manufacturer.<\/p>\n<\/div>\n \ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n Rcifax is supplied from a produc\u0103tor certificat WHO-GMP<\/strong>. Fiecare comand\u0103 este expediat\u0103 discret \u00een \u00eentreaga lume \u0219i este acoperit\u0103 de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a> — if it does not arrive within 20 business days, we reship at no cost. Rifaximin is endorsed by AASLD 2021 for hepatic encephalopathy prevention and by ACG 2021 for traveller’s diarrhoea and IBS-D — one of the few antibiotics with strong evidence in functional GI disorders.<\/p>\n Rifaximin binds the β-subunit of bacterial DNA-dependent RNA polymerase (rpoB), inhibiting bacterial RNA synthesis. Spectrum covers Gram-positive and Gram-negative aerobes and anaerobes including E. coli, Shigella, Salmonella, Campylobacter, and many enteric anaerobes. Because absorption is < 0.4 percent of the oral dose, the drug acts effectively only on intra-luminal organisms.<\/p>\nDe ce s\u0103 comanzi de la MedsBase<\/h3>\n
De ce s\u0103 comanzi de la MedsBase<\/h3>\n
Mecanism de ac\u021biune<\/h2>\n
Indica\u021bii & doze<\/h2>\n